Vaxcyte Inc (PCVX)'s VAX-31 Enters Critical Trial Stage [Yahoo! Finance]
Vaxcyte, Inc. (PCVX)
Company Research
Source: Yahoo! Finance
The company announced this development on March 23, stating that it enrolled approximately 4,000 participants in the OPUS-1 trial and 1,300 in the OPUS-2 trial. Vaxcyte Inc (PCVX)'s VAX-31 Enters Critical Trial Stage M. A. Arkhipov/Shutterstock.com Vaxcyte's vaccine candidate VAX-31 is intended to prevent invasive pneumococcal disease and pneumonia in adults. It's also being tested in infants. The two Phase 3 trials that have completed enrollment are focused on adults. In the OPUS-1 trial, VAX-31's safety, tolerability, and immune response will be evaluated against two current standard pneumococcal vaccines. This study has two cohorts. It includes adults aged 50 years and older, and a separate group of adults aged 18 – 49 years. This study is being conducted at around 50 sites across the US, and its topline results are expected in Q4 2026. The OPUS-2 trial will also evaluate the safety, tolerability, and immune response of VAX-31 in adults aged 50 and older. But in this stud
Show less
Read more
Impact Snapshot
Event Time:
PCVX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PCVX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PCVX alerts
High impacting Vaxcyte, Inc. news events
Weekly update
A roundup of the hottest topics
PCVX
News
- Vaxcyte (PCVX) was downgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=PCVX&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "sell" to "stroMarketBeat
- Vaxcyte (PCVX) was upgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=PCVX&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "strong sell" to MarketBeat
- Vaxcyte (PCVX) was downgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=PCVX&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "sell" to "stroMarketBeat
- Vaxcyte (PCVX) had its "sell (d-)" rating reaffirmed by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference [Yahoo! Finance]Yahoo! Finance
PCVX
Earnings
- 2/24/26 - Miss
PCVX
Sec Filings
- 4/23/26 - Form DEFA14A
- 4/23/26 - Form DEF
- 4/23/26 - Form ARS
- PCVX's page on the SEC website